Clinical Trials Logo

Filter by:
NCT ID: NCT06172309 Active, not recruiting - Clinical trials for Advanced Solid Tumors

A Phase I Study of NTQ1062 in Chinese Patients With Advanced Solid Tumors

Start date: September 13, 2021
Phase: Phase 1
Study type: Interventional

This is an open-label, single-arm, phase 1 study to evaluate the safety, tolerability, pharmacokinetics, and preliminary pharmacodynamic effect of NTQ1062 in patients with advanced solid tumors. The study comprises a dose-escalation phase and a dose-expansion phase. 1. Dose-escalation:using 3+3 design to evaluate the safety, tolerability, and pharmacokinetic profile of NTQ1062 at 20, 50, 100, 200, 300, 400 mg in patients with advanced solid tumors, and to determine the maximum tolerated dose (MTD). 2. Dose-expansion:the dose-expansion study will evaluate the safety, tolerability, and preliminary pharmacodynamic effect of the MTD for NTQ1062 in patients with advanced solid tumors, and to identify the recommended phase 2 dose (RP2D).

NCT ID: NCT06170307 Active, not recruiting - COVID-19 Pandemic Clinical Trials

Left Atrial Function of COVID-19-recovered Patients During the Surge of Omicron Variants

Start date: November 20, 2023
Phase:
Study type: Observational

The goal of this observational study is to retrospectively analyze left atrial function in mild to moderate COVID-19-recovered patients. The main questions it aims to answer are: - Whether left atrial function is involved in patients with mild to moderate COVID-19 after recovery. - What are the factors that may be associated with persistent heart-related symptoms (including chest pain, chest tightness, palpitations, shortness of breath, or postural tachycardia) in patients with mild to moderate COVID-19 ? Participants will undergo transthoracic echocardiography to obtain conventional ultrasound parameters, two-dimensional strain parameters will been obtained through software post-processing, and general clinical data and laboratory test results will been obtained.

NCT ID: NCT06170216 Active, not recruiting - Clinical trials for Lymphoma, Non-Hodgkin

Different Immunochemotherapies in Small B-cell Non-Hodgkin Lymphoma (iNHL)

Start date: January 10, 2023
Phase:
Study type: Observational

Describe the application status of different immunochemotherapies in small B-cell non-Hodgkin lymphoma (iNHL), observe the therapeutic efficacy and safety of the treatment modalities.

NCT ID: NCT06170086 Active, not recruiting - Stroke, Acute Clinical Trials

Early Neurological Trajectory and Clinical Outcomes in Brain Acute Ischemic Stroke

Start date: September 1, 2023
Phase:
Study type: Observational

Prospective identification of potential responsible blood vessels, provision of intervention targets, prevention of fatal and disabling cerebrovascular diseases, identification of early END patients, determination of clinical treatment pathways, improvement of efficacy, and improvement of prognosis

NCT ID: NCT06155110 Active, not recruiting - Clinical trials for Cardiovascular Diseases

A Randomized, Single-blind, Controlled Clinical Study of Cardiomyopeptidin on Improving Ischemia-reperfusion Injury in Patients With Acute ST-segment Elevation Myocardial Infarction After Primary PCI

Start date: March 1, 2022
Phase: Phase 4
Study type: Interventional

This study aim to investigate the myocardium protection effect of cardiomyopeptidin in patients undergoing primary PCI for ST-elevation myocardial infarction through myocardial enhanced MRI.

NCT ID: NCT06153069 Active, not recruiting - Tuberculosis Clinical Trials

Subclinical TB With Innovative Modified Short-course Regimens

SWIFT
Start date: November 1, 2023
Phase: Phase 4
Study type: Interventional

This study is a randomized controlled trial among subclinical tuberculosis patients aiming to assess whether the standard treatment duration can be shortened to 17 weeks or even 8 weeks without changing the current anti-tuberculosis drugs or dosages.

NCT ID: NCT06150521 Active, not recruiting - Clinical trials for Hysteroscopic Myomectomy

Hysteroscopic Myomectomy for Submucosal Myomas Without Energy Instruments

Start date: May 23, 2023
Phase:
Study type: Observational

Uterine fibroid are the most common benign tumor in the female reproductive system. Although many patients with uterine fibroid do not need to be treated because they are asymptomatic, some patients can experience compression, menorrhagia, pain, irregular bleeding or infertility. The symptoms caused by uterine fibroid are related to its location and size. Submucous fibroids constitute 5-10% of all uterine fibroids.The submucous hysteromyoma is the most likely to cause symptoms, often leads to menorrhagia, irregular bleeding or infertility. Hysteroscopic myomectomy is a commonly used minimally invasive procedure. The submucous myoma can be resected out by endoscopic resectoscope with electricloop (unipolar and bipolar) . It can preserve the uterus and fertility, also effectively alleviate symptoms. However, some specific complications have also followed,such as: hemorrhage,uterine perforation, pneumonedema,infections,adhesions,etc. Uterine perforation occurs when the electrode is working, there is a high risk of injury to adjacent anatomical structures. And even without perforation, sometimes thermal injury to adjacent organs may still be discovered in a few days after surgery.In addition,Many scholars have found that hysteroscopic electromyectomy has a higher risk of intrauterine adhesion than other intrauterine operations. In order to reduce the damage caused by energy source, especially the adverse effects of thermal damage on the endometrium, the new methods of hysteroscopic myomectomy currently include: the hysteroscopic tissue removal (HTR) system, the cold loop myomectomy, the Hysteroscopy Endo Operative system (HEOS),etc. Existing studies show that,These manipulation techniques did not cause the myometrium damage by radiofrequency energy source, greatly reducing the risk of postoperative intrauterine adhesions. The cold knife hysteroscopic myomectomy in this study is a series of procedures using cold instruments(mechanically, with scissor, grasping or morcellation) to remove uterine submucosal fibroids. The purpose of this surgical technique is to make the operation safe and effective, with greater emphasis on the anatomical and physiological integrity of the myometrial and endometrial layers. This study aims to evaluate the safety and efficacy of cold knife hysteroscopic myomectomy.

NCT ID: NCT06143644 Active, not recruiting - Colorectal Cancer Clinical Trials

Predictive Value of Postoperative Circulating Tumor DNA Monitoring for Colorectal Cancer Recurrence

Start date: January 15, 2022
Phase:
Study type: Observational

This observational study aims to assess the predictive value of postoperative circulating tumor DNA (ctDNA) monitoring in evaluating the risk of recurrence in stage I-IV colorectal cancer patients. The study involves the collection of blood samples from patients who have undergone surgery for colorectal cancer. Sensitivity-enhanced molecular biology techniques are utilized to detect ctDNA in these samples. The correlation between ctDNA detection and the risk of recurrence is evaluated by analyzing patient follow-up data and clinical information. The findings of this study may contribute to the development of improved postoperative management strategies, such as identifying high-risk individuals and implementing additional treatment measures to reduce the risk of recurrence.

NCT ID: NCT06141551 Active, not recruiting - Disc Herniation Clinical Trials

Intradural Disc Herniation: a Case Report and Review of Complications

Start date: October 1, 2023
Phase:
Study type: Observational

This observational study collects clinical data as well as pathological reports from a patient with an intradural disc herniation, reports on the course of the patient's recovery through surgical treatment, summarizes the complications of this type of disease, and provides new ideas for improving the chances of preoperative diagnosis.

NCT ID: NCT06141304 Active, not recruiting - Relapsed Adult AML Clinical Trials

Plerixafor Plus Donor Lymphocyte Infusion for Relapsed Acute Leukemia After Allo-HSCT

Start date: September 1, 2023
Phase: Phase 2
Study type: Interventional

Acute leukemia, including acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL), is the subtype of leukemia with the highest mortality, and leukemia relapse caused by the protective bone marrow microenvironment is the main cause of treatment failure. The chemokine receptor CXCR4 plays a crucial role in the homing and settling of leukemia cells into the bone marrow. Preclinical study of the investigators demonstrates that CXCR4 blockade can mobilize leukemia cells from their protective bone marrow microenvironment to periphery, thereby significantly enhancing the killing effect of allogeneic lymphocytes against leukemia cells. This study aims to preliminarily evaluate the efficacy and safety of donor lymphocyte infusion (DLI) plus CXCR4 antagonist plerixafor in the treatment of relapsed acute leukemia patients after allogeneic hematopoietic stem cell transplantation (allo-HSCT) through a prospective single arm study. The results may preliminarily confirm the effectiveness and safety of DLI combined with plerixafor in the treatment of recurrent acute leukemia patients after allo-HSCT, providing a reference basis for further research.